Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
HORIBA
| Company | HORIBA |
|---|---|
| Name of analyzer | ABX Micros ES60 |
| Contact | Susan Behnke |
| City, State | Irvine, CA |
| Phone | 888-903-5001 |
| Website | |
| Analyzer application | diagnostic use |
| Dimensions of analyzer (H × W × D)/Analyzer footprint | 16.9 × 14.2 × 14.2 in./1.4 sq. ft. |
| Country where analyzer was designed/Manufactured | —/France |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S. (based on August 2026 survey deadline) | 2014/>2,000 |
| First year analyzer sold outside U.S./Approximate No. of units installed outside U.S. (based on August 2026 survey deadline) | —/>18,000 |
| Foreign locations where company markets analyzer | South America, Europe, Asia, Africa, Middle East |
| Human languages (other than English) supported by analyzer | — |
| Analyzer list price | — (slide maker stainer sold separately) |
| • Analyzer acquisition options | purchase, trade in, lease, reagent rental agreement |
| Training included with purchase/Total time for basic training per operator | yes/— (at customer site) |
| • Follow-up training available | yes (no extra charge) |
| Parameters that analyzer tests and reports | %&# lymphocytes, %&# monocytes, %&# granulocytes, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, WBC |
| Types of testing FDA cleared or approved for analyzer | blood count analysis |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | — |
| Differential methods used | impedance, specific lyse action |
| Analytical measurement range: • WBC count/RBC count | WBC: 0–100 × 103/mm3/RBC: 0–8 × 106/mm3 |
| Precision: • WBC count/RBC count | WBC: <2.5% CV/RBC: <2.0% CV |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | multiple myeloma, hemolysis, platelet agglutination, chemotherapy, cryoglobulins/agglutinated RBCs, cold agglutinins |
| • Hemoglobin/Platelets | elevated lipemia, increased turbidity/RBC agglutination, chemotherapy, hemolysis, platelet agglutination |
| • Hematocrit/Reticulocytes | RBC agglutination/— |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | —/60 |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | — |
| Min. specimen volume open mode/Closed mode/Microsample capability | 10 μL/10 μL/yes |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | — |
| Analyzer performs delta checks | no |
| Parameters for which flags may appear | — |
| • Flagging client selectable | combination of client and vendor selectable |
| Analyzer recognizes and holds test results | yes, for potential test rerun (parameters for flags to hold samples defined by client or vendor) |
| Scattergram display uses cell-specific color | no |
| Histogram display uses color with thresholds | yes |
| LIS interface formats supported | proprietary (analyzer or vendor specific), ASTM 1394-91, ASTM 1238-95, ASTM 1381, HL7 version 2, HL7 version 3 |
| • Middleware interface | yes |
| Analyzer transmits LOINC codes for results to LIS or middleware | — |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Data Matrix, Code 39, Code 128 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes |
| No. of onboard reagents required for standard specimen analysis | 3 |
| • Reagents ready to use/Reagent tracking method | yes/barcode reader |
| Time required for analyzer maintenance | 10 min. weekly |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/— |
| Distinguishing analyzer features (supplied by company) | real-time instrument status with help messages; sample tube holder with 16 tube sizes |
| Note | ‡all information listed was provided to CAP TODAY in 2025; company did not provide updated information by 2026 entry deadline |